Madrigal Pharmaceuticals (MDGL) Projected to Post Earnings on Wednesday

Madrigal Pharmaceuticals (NASDAQ:MDGL) will likely be releasing its earnings data before the market opens on Wednesday, February 26th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($4.32) per share and revenue of $97.81 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Madrigal Pharmaceuticals Stock Down 4.2 %

Madrigal Pharmaceuticals stock opened at $322.14 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. Madrigal Pharmaceuticals has a 1-year low of $189.00 and a 1-year high of $368.29. The company has a market cap of $7.03 billion, a PE ratio of -12.84 and a beta of -0.38. The stock’s 50 day moving average price is $320.09 and its 200 day moving average price is $282.67.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MDGL. JMP Securities restated a “market outperform” rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. UBS Group lifted their price target on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a research note on Friday, November 1st. B. Riley boosted their target price on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright boosted their target price on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.67.

Insider Activity

In other news, VP Robert E. Waltermire sold 103 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $34,529.72. Following the sale, the vice president now directly owns 4,955 shares in the company, valued at $1,661,114.20. This represents a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carole Huntsman sold 347 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $116,328.28. Following the completion of the sale, the insider now owns 10,438 shares in the company, valued at $3,499,235.12. This represents a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,690 shares of company stock worth $2,692,601 over the last three months. 22.80% of the stock is currently owned by corporate insiders.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.